JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease
The FDA bestows a Fast Track designation to Johnson & Johnson's nipocalimab for treating moderate-to-severe Sjogren's disease ...
Applied Clinical Trials Online4d
Phase II DAHLIAS Trial Results Lead to Fast Track Designation for Nipocalimab for Sjögren’s Disease
FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to ...
Pharmabiz6d
US FDA grants Fast Track designation to Johnson & Johnson’s nipocalimab to treat adult patients with moderate-to-severe Sjögren’s disease
Spring House, Pennsylvania Wednesday, March 19, 2025, 14:00 Hrs [IST] ...
Medical Dialogues6d
JnJ Nipocalimab gets USFDA Fast Track designation for Sjogren's disease
House: Johnson & Johnson has received Fast Track designation (FTD) from the U.S. Food and Drug Administration (FDA) for ...
HDFN Companion1d
What is a Coombs test?
Learn more about a Coombs test and how it is used as part of standard prenatal screening in the U.S. to detect HDFN.
HDFN Companion1d
Increased testing for Rh, Kell phenotypes could reduce HDFN risk
Increased testing for Rh and Kell phenotypes could reduce the risk of adverse transfusion reactions and HDFN, a study found.